We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 2 of 107 for:    RC18

A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04302103
Recruitment Status : Active, not recruiting
First Posted : March 10, 2020
Last Update Posted : January 11, 2022
Information provided by (Responsible Party):
RemeGen Co., Ltd.

Brief Summary:
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis.

Condition or disease Intervention/treatment Phase
Systemic Myasthenia Gravis Biological: RC18 160mg Biological: RC18 240 mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Systemic Myasthenia Gravis
Actual Study Start Date : July 23, 2020
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RC18 160mg
Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
Biological: RC18 160mg
subcutaneous injection

Experimental: RC18 240 mg
Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
Biological: RC18 240 mg
subcutaneous injection

Primary Outcome Measures :
  1. The average variation of QMG scores of the twenty-fourth week compared to the QMG scores of baseline [ Time Frame: week 24 ]
    QMG score=Quantitative Myasthenia Gravis Score

Secondary Outcome Measures :
  1. The average variation of clinical absolute score for myasthenia gravis of the twelfth and twenty-fourth weeks compared to Clinical absolute score for myasthenia gravis of baseline [ Time Frame: week 12,24 ]
    It is best that the assessors in each center are fixed during the study.

  2. The average variation of QMG score of the twelfth week compared to the OMG scores of baseline [ Time Frame: week 12 ]
    QMG score=Quantitative Myasthenia Gravis Score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Voluntarily signed informed consent ;
  2. Patient diagnosed with systemic myasthenia gravis according to The following conditions.
  3. Seropositive at screening for AChR(Acetylcholine receptor)-Ab or MuSK(Muscle specific tyrosine kinase)-Ab;
  4. MGFA(Myasthenia Gravis Foundation of America) Clinical classification Ⅱ-IIIb;
  5. QMG score≥8,and QMG score>2 in four or more items;
  6. Maintained any one of the stable standard treatment programs in the trial protocol.

Exclusion Criteria:

  1. Combined autoimmune diseases, such as systemic lupus erythematosus,rheumatoid arthritis, systemic sclerosis and so on,except for hypothyroidism and hyperthyroidism;
  2. Abnormal laboratory parameters need to be excluded, including but not limited to:
  3. Immunosuppressive agents except agents of standard treatment programs were used within one month prior to randomization.;
  4. Use of biological agents for targeted therapy within 6 months prior to randomization;
  5. Intravenous immunoglobulin therapy or plasma exchange therapy within 2 months before randomization;
  6. Active infection during screening(For example,herpes zoster,HIV antibody positive,active tuberculosis,etc);
  7. Currently suffering from active hepatitis or severe liver lesions and history;
  8. Diabetics with poor blood sugar control:HbAlc>9.0% or FBG≥11.1mmol/L;
  9. Currently having a thymic tumor ,or had a thymectomy within 6 months prior to screening;
  10. Received live vaccines within 3 months before randomization,or scheduled to administer vaccine during the trial;
  11. Malignant tumor patients;
  12. Allergic to human biological preparations;
  13. Have participated in any clinical trial within 28 days before randomization,or in 5 times half-life period of the drugs of any clinical trial(taking the longer time).
  14. Pregnant , lactating women and men or women who have birth plans during the research;
  15. Having alcohol or drug abuse that affect the experimental conditions;
  16. Investigator considers candidates not appropriating for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04302103

Layout table for location information
China, Beijing
Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing, China, 100070
Sponsors and Collaborators
RemeGen Co., Ltd.
Layout table for investigator information
Principal Investigator: Xianhao Xu, M.D. Beijing Hospital
Layout table for additonal information
Responsible Party: RemeGen Co., Ltd.
ClinicalTrials.gov Identifier: NCT04302103    
Other Study ID Numbers: 18C011
First Posted: March 10, 2020    Key Record Dates
Last Update Posted: January 11, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Myasthenia Gravis
Muscle Weakness
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Paraneoplastic Syndromes, Nervous System
Nervous System Neoplasms
Neoplasms by Site
Paraneoplastic Syndromes
Autoimmune Diseases of the Nervous System
Neurodegenerative Diseases
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases